Autonomix Medical Files 8-K
Ticker: AMIX · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1617867
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Autonomix Medical filed a routine 8-K, no major news.
AI Summary
Autonomix Medical, Inc. filed an 8-K on June 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a standard disclosure for Autonomix Medical, Inc., informing the public about regulatory compliance and the submission of financial documents.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosure and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Autonomix Medical, Inc. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41940 (file_number) — SEC File Number
- 47-1607810 (tax_id) — I.R.S. Employer Identification No.
- 21 Waterway Avenue, Suite 300 (address) — Principal executive offices
- The Woodlands, TX (location) — Principal executive offices location
- 77380 (zip_code) — Principal executive offices zip code
- ( 713 ) 588-6150 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Autonomix Medical, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as indicated by the filing's item information.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 18, 2024.
In which U.S. state is Autonomix Medical, Inc. incorporated?
Autonomix Medical, Inc. is incorporated in Delaware.
What is the SEC file number for Autonomix Medical, Inc.?
The SEC file number for Autonomix Medical, Inc. is 001-41940.
What is the business address of Autonomix Medical, Inc.?
The business address of Autonomix Medical, Inc. is 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.
Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-18 08:05:35
Key Financial Figures
- $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
Filing Documents
- amix20240617_8k.htm (8-K) — 28KB
- ex_689438.htm (EX-99.1) — 27KB
- ex_689814.htm (EX-99.2) — 8KB
- a01.jpg (GRAPHIC) — 85KB
- a02.jpg (GRAPHIC) — 131KB
- a03.jpg (GRAPHIC) — 82KB
- a04.jpg (GRAPHIC) — 66KB
- logo.jpg (GRAPHIC) — 2KB
- slide01.jpg (GRAPHIC) — 139KB
- slide02.jpg (GRAPHIC) — 286KB
- slide03.jpg (GRAPHIC) — 116KB
- slide04.jpg (GRAPHIC) — 128KB
- slide05.jpg (GRAPHIC) — 194KB
- slide06.jpg (GRAPHIC) — 210KB
- slide07.jpg (GRAPHIC) — 138KB
- slide08.jpg (GRAPHIC) — 129KB
- slide09.jpg (GRAPHIC) — 175KB
- slide10.jpg (GRAPHIC) — 193KB
- slide11.jpg (GRAPHIC) — 157KB
- slide12.jpg (GRAPHIC) — 126KB
- slide13.jpg (GRAPHIC) — 86KB
- 0001437749-24-020591.txt ( ) — 3577KB
- amix-20240618.xsd (EX-101.SCH) — 3KB
- amix-20240618_def.xml (EX-101.DEF) — 12KB
- amix-20240618_lab.xml (EX-101.LAB) — 15KB
- amix-20240618_pre.xml (EX-101.PRE) — 12KB
- amix20240617_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On June 18, 2024, Autonomix Medical, Inc. (the "Company") issued a press release, which announced preliminary positive results from the first five "lead-in" patients in the Company's ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. On June 18, 2024, the Company utilized an updated slide presentation for its PoC human clinical trial as part of the Company's webcast presentation on Tuesday, June 18, 2024 at 8:30 a.m. ET. A copy of these press releases are attached to this report as Exhibits 99.1 and 99.2 and are incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, are being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall they be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated June 18, 2024. 99.2 Corporate Slide Presentation dated June 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: June 18, 2024